Tyr1092

Site Information
AFLPVPEyVNQSVPK SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 448057
Associated spectra: 1 CST

In vivo Characterization
Methods used to characterize site in vivo:	immunoassay ( 12 ) , mass spectrometry ( 11 , 14 , 15 , 16 , 17 , 18 , 19 , 20 ) , phospho-antibody ( 5 , 6 , 7 , 8 , 9 , 10 , 12 , 13 , 21 , 22 , 23 ) , western blotting ( 5 , 6 , 7 , 8 , 9 , 10 , 12 , 13 , 21 , 22 )
Disease tissue studied:	bladder cancer ( 13 ) , lung cancer ( 22 ) , neurofibromatosis type 1 ( 10 )
Relevant cell line - cell type - tissue:	3T3 (fibroblast) [Src (human)] ( 22 ) , ASZ001 (epidermal) ( 6 ) , BaF3 ('B lymphocyte, precursor') [EGFR (human)] ( 22 ) , bEnd3 ( 8 ) , bladder ( 13 ) , BV2 (microglia) ( 7 ) , hair follicle ( 12 ) , HTR8/SVneo (trophoblast) ( 5 ) , keratinocyte ( 12 ) , keratinocyte-skin ( 23 ) , liver ( 11 , 18 , 19 , 20 ) , liver [Akt2 (mouse), homozygous knockout] ( 15 , 16 , 17 ) , MEF (fibroblast) [PTP1B (mouse), homozygous knockout] ( 14 ) , MEF (fibroblast) ( 14 ) , neural crest ( 10 ) , S462TY (neural crest) ( 10 ) , squamous ( 6 )

Upstream Regulation
Regulatory protein:	EGFR (mouse) ( 9 ) , Fos (human) ( 6 ) , PLA1A (mouse) ( 12 ) , PTP1B (mouse) ( 14 )
Phosphatases, in vitro:	PTP1B (mouse) ( 14 )
Treatments:	AG1478 ( 5 , 7 , 9 , 12 ) , Astragaloside-III ( 8 ) , astragaloside_IV ( 9 ) , EGF ( 5 , 10 , 12 , 14 , 21 ) , erlotinib ( 8 ) , gefitinib ( 22 ) , LPA ( 12 ) , morphine ( 7 ) , okadaic_acid ( 22 ) , OSI-774 ( 10 ) , SB202190 ( 21 ) , SB203580 ( 8 ) , TAPI-0 ( 8 ) , UV ( 23 )

Downstream Regulation
Effects of modification on EGFR:	activity, induced ( 12 ) , enzymatic activity, induced ( 8 ) , phosphorylation ( 12 )
Effects of modification on biological processes:	apoptosis, inhibited ( 23 ) , carcinogenesis, altered ( 6 ) , carcinogenesis, induced ( 5 , 7 ) , cell differentiation, induced ( 6 , 12 ) , cell motility, induced ( 7 ) , signaling pathway regulation ( 8 ) , transcription, altered ( 6 ) , transcription, inhibited ( 5 )

References
1	Bhatia R, et al. (2023) Muc4 loss mitigates epidermal growth factor receptor activity essential for PDAC tumorigenesis. Oncogene 36624189 Curated Info
2	Kang J, et al. (2022) EGFR-phosphorylated GDH1 harmonizes with RSK2 to drive CREB activation and tumor metastasis in EGFR-activated lung cancer. Cell Rep 41, 111827 36516759 Curated Info
3	Jin C, et al. (2022) MTDH-stabilized DDX17 promotes tumor initiation and progression through interacting with YB1 to induce EGFR transcription in Hepatocellular Carcinoma. Oncogene 42 36385375 Curated Info
4	Celen C, et al. (2022) Arid1a loss potentiates pancreatic β-cell regeneration through activation of EGF signaling. Cell Rep 41, 111581 36323264 Curated Info
5	Fang L, et al. (2021) EGF stimulates human trophoblast cell invasion by downregulating ID3-mediated KISS1 expression. Cell Commun Signal 19, 101 34620174 Curated Info
6	Kuonen F, et al. (2021) c-FOS drives reversible basal to squamous cell carcinoma transition. Cell Rep 37, 109774 34610301 Curated Info
7	Yang Y, et al. (2021) Morphine promotes microglial activation by upregulating the EGFR/ERK signaling pathway. PLoS One 16, e0256870 34520454 Curated Info
8	Wang H, et al. (2020) Astragaloside III activates TACE/ADAM17-dependent anti-inflammatory and growth factor signaling in endothelial cells in a p38-dependent fashion. Phytother Res 34 32197276 Curated Info
9	Gu DM, et al. (2015) EGFR mediates astragaloside IV-induced Nrf2 activation to protect cortical neurons against in vitro ischemia/reperfusion damages. Biochem Biophys Res Commun 457, 391-7 25582778 Curated Info
10	Wu J, et al. (2014) EGFR-STAT3 signaling promotes formation of malignant peripheral nerve sheath tumors. Oncogene 33, 173-80 23318430 Curated Info
11	Grimsrud PA, et al. (2012) A quantitative map of the liver mitochondrial phosphoproteome reveals posttranslational control of ketogenesis. Cell Metab 16, 672-83 23140645 Curated Info
12	Inoue A, et al. (2011) LPA-producing enzyme PA-PLA₁α regulates hair follicle development by modulating EGFR signalling. EMBO J 30, 4248-60 21857648 Curated Info
13	Bhuvaneswari R, Gan YY, Soo KC, Olivo M (2009) Targeting EGFR with photodynamic therapy in combination with Erbitux enhances in vivo bladder tumor response. Mol Cancer 8, 94 19878607 Curated Info
14	Mertins P, et al. (2008) Investigation of protein-tyrosine phosphatase 1B function by quantitative proteomics. Mol Cell Proteomics 7, 1763-77 18515860 Curated Info
15	Guo A (2007) CST Curation Set: 2987; Year: 2007; Biosample/Treatment: tissue, liver/-; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
16	Guo A (2007) CST Curation Set: 2988; Year: 2007; Biosample/Treatment: tissue, liver/-; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
17	Guo A (2007) CST Curation Set: 2989; Year: 2007; Biosample/Treatment: tissue, liver/Insulin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
18	Guo A (2007) CST Curation Set: 2984; Year: 2007; Biosample/Treatment: tissue, liver/-; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
19	Guo A (2007) CST Curation Set: 2985; Year: 2007; Biosample/Treatment: tissue, liver/Insulin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
20	Guo A (2007) CST Curation Set: 2986; Year: 2007; Biosample/Treatment: tissue, liver/Insulin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
21	Frey MR, Dise RS, Edelblum KL, Polk DB (2006) p38 kinase regulates epidermal growth factor receptor downregulation and cellular migration. EMBO J 25, 5683-92 17139251 Curated Info
22	Sharma SV, et al. (2006) A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenes. Cancer Cell 10, 425-35 17097564 Curated Info
23	El-Abaseri TB, Putta S, Hansen LA (2006) Ultraviolet irradiation induces keratinocyte proliferation and epidermal hyperplasia through the activation of the epidermal growth factor receptor. Carcinogenesis 27, 225-31 16123117 Curated Info